ProCE Banner Activity

Future Applications in ES-SCLC: Targeting DLL3 and Emerging Evidence for T-Cell Engagers

Slideset

Download this slideset to learn the latest about T-cell–engaging therapies targeting DLL3 in extensive-stage small-cell lung cancer (ES-SCLC).

Released: November 07, 2024

Expiration: May 06, 2025

Share

Faculty

Carl M. Gay

Carl M. Gay, MD, PhD

Assistant Professor
Thoracic/Head & Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.